Quercetin and Airway Inflammation: Mechanism and Honest Limits

A well-characterised mechanism with a genuine absorption problem. Both halves are worth knowing.

What mast cells do in airways

Mast cells sit in airway tissue loaded with granules containing histamine, leukotrienes, prostaglandins and cytokines. When triggered — by allergen, irritant or certain physical stimuli — they degranulate, releasing the contents into surrounding tissue.

The downstream effects are exactly what you would not want in an airway. Smooth muscle contracts, narrowing the bronchus. Vascular permeability increases, producing tissue oedema that narrows it further. Goblet cells increase mucus secretion. Sensory nerves are sensitised, which drives cough.

This is a cause of narrowing rather than a consequence, which is why intervening here is mechanistically different from clearing mucus that has already formed.

What quercetin is studied to do

Quercetin has been examined as a mast cell stabiliser — reducing the likelihood and extent of degranulation rather than blocking histamine after release, which is what antihistamines do.

Its anti-allergic immune response profile has been reviewed in the flavonoid literature, and it has additional documented antioxidant activity and effects on inflammatory signalling pathways.

The mechanistic case is reasonable and the in-vitro evidence is fairly consistent.

The bioavailability problem, stated plainly

Here is where honesty matters. Quercetin's oral bioavailability is poor. Standard quercetin aglycone is absorbed inefficiently, extensively metabolised in the gut wall and liver, and cleared relatively quickly.

This creates a gap between in-vitro concentrations that produce clear effects and plasma concentrations achievable from oral dosing. Anyone citing cell-culture results as though they translate directly to a capsule is skipping a significant step.

Various approaches attempt to address this — different glycoside forms, phytosome complexes, co-administration with bromelain or vitamin C, liposomal delivery. Some have supporting data. None fully solves it.

Mucosal delivery via spray bypasses first-pass hepatic metabolism for the fraction absorbed there, which is a partial mitigation rather than a complete answer.

Dietary sources

Quercetin is abundant in ordinary food: onions, particularly red onion skin layers, apples with skin, capers, kale, broccoli, berries, tea and red wine.

Reaching supplement-range intakes from diet alone is impractical, but there is a reasonable argument that food-form quercetin arrives with cofactors and other flavonoids that may matter. Eating more onions and apples is not a competing strategy to supplementation; it is a complementary one with no downside.

Interactions

• Quinolone antibiotics. Quercetin may compete for the same bacterial target, potentially reducing effectiveness. Separate dosing.
• CYP-metabolised drugs. Quercetin inhibits certain cytochrome P450 enzymes, which can affect levels of drugs cleared by those pathways.
• Ciclosporin. Documented interaction.
• Anticoagulants. Possible mild additive antiplatelet effect.

A measured position

Quercetin has a coherent, well-characterised mechanism relevant to airway inflammation, real in-vitro support, and a genuine absorption limitation that constrains how much of that translates in practice.

It is a sensible inclusion in a multi-ingredient airway formula. It would be an overstatement to present it as the primary driver of any respiratory outcome.